

ROBERT LYNN HORNE, MD, Ltd.
3025 W. Sahara Ave. Ste 200
Las Vegas, NV 89102
Office: (702)822-1188
Fax: (702)822-2020

December 6, 2021

Pharmacy and Therapeutics Committee
State of Nevada Department of Health and Human Services
Division of Health Care Financing and Policy
1100 E. William Street, Suite 101
Carson City, Nevada 89701

Re: December 9, 2021 Agenda item 5.f.

Dear Committee Members:

I am writing to request you to add Caplyta (Lumateperone) to the Nevada Medicaid Preferred Antipsychotic Drug List at your December 9, 2021, meeting.

I have never been paid to research or speak for this medication, but I have found Caplyta to be useful for many of my patients suffering from Schizophrenia.

Of course, like all other FDA approved antipsychotics, 2 Clinical trials showed Caplyta (Lumateperone) had statistically superior efficacy vs placebo in treating Schizophrenia

It's advantages over many of the other medications on the preferred list include the following:

1. Once a day dosing and it does not need to be titrated as do many others in the same class.
2. No significant difference from placebo in lipids, glucose, prolactin, or weight in clinical trials.
3. EPS profile was similar to placebo and its incidence of Akathisia was 2.0% vs 2.9% for placebo.

In summary, its efficacy, along with the simplicity of once-a-day dosing with no titration and a safety profile similar to placebo is beneficial to both patients and prescribers.

I appreciate your considering adding Caplyta to the Nevada Medicaid Preferred Formulary.

Sincerely yours,



Robert Lynn Horne, MD
Distinguished Life Fellow, American Psychiatric Association
Diplomate, American Board of Psychiatry and Neurology
Diplomate, American Board of Forensic Medicine
Diplomate, American Academy of Pain Management